Last updated on February 2018

Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During PCI (ONSIDE TEST)

Brief description of study

Patients undergoing percutaneous coronary intervention with a residual high platelet reactivity despite oral clopidogrel are at increased risk of ischaemic complications. The strategies to overcome the issue consist of switch to a more potent antiplatelet medications including prasugrel or ticagrelor. Economic constrains of many countries still do not allow wide reimbursement of newer antiplatelet agents. Therefore a strategy to personalise treatment according to genotype and phenotype characteristics of the patient may provide an attractive solution combining high clinical efficacy with low budget impact.

Clinical Study Identifier: NCT01930773

Contact Investigators or Research Sites near you

Start Over

Lukasz Koltowski, MD, PhD

Heart Center Balatonf red
Balatonfüred, Hungary
  Connect »

Lukasz Koltowski, MD

1st Department of Cardiology, Medical University of Warsaw
Warsaw, Poland
  Connect »